MAMA
1–2% of women are affected by inflammatory arthritis such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, or juvenile idiopathic arthritis. Many are treated with new medications known as 'biologics'. More women with inflammatory arthritis are considering starting a family, because treatment with biologics means they are more able to manage their arthritis. It is not a straightforward decision when it comes to stopping or continuing biologic medications in the second half of pregnancy. We don't know the impact of stopping or continuing biologics on how well a person's arthritis is controlled in pregnancy or in the postnatal period (after the baby is born). The MAMA study is looking to answer this question.
Key information to know about MAMA:
- Both continuing and stopping using biologics beyond 28 weeks of pregnancy are routine practice in the UK
- Women who take part in the study will be randomly allocated to either continue taking their biologic throughout pregnancy, or to stop by 28 weeks gestation
- We will collect information about participants and their babies
- This study is being run in 35 hospitals in the UK
- The study will run for about 4 years
About Us
MAMA is coordinated by the National Perinatal Epidemiology Unit Clinical Trial Unit (NPEU CTU) at the University of Oxford and is funded by the National Institute of National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) programme.
